AMBER announces research collaboration to transform orthopaedic treatments
04 September 2018
L-R: Dr Lorraine Byrne, executive director, AMBER & CRANN, Trinity; Dr Joseph M Ault, senior fellow, API, and bioprinting lead, 3D Printing Center of Excellence, Johnson & Johnson; Prof Danny Kelly, AMBER principal investigator, School of Engineering, Trinity, and director of the TCBE; Dr Gráinne Cunniffe, project manager/staff engineer, 3D Printing Center of Excellence, Johnson & Johnson
AMBER, the Science Foundation Ireland (SFI) Research Centre for materials science based at Trinity, has announced a research collaboration with DePuy Ireland Unlimited Company and Johnson & Johnson Services, Inc.
The overall goal of TRANSITION, the five-year project funded under SFI’s Spokes programme, is to develop a new class of 3D-printed biological implants that will regenerate, rather than replace, diseased joints.
‘Potential to transform how we treat degenerative diseases’
This project has the potential to transform how we treat degenerative diseases such as osteoarthritis, which at present affects around 915,000 people in Ireland and is thought to affect 10 per cent of the world’s population over the age of 60. SFI has provided 35 per cent of the funding, with the remainder provided by DePuy Ireland Unlimited Company and Johnson & Johnson Services, Inc.
Orthopaedic medicine involves treating conditions that affect the bones, soft tissue and joints. 3D-printing has the potential to transform treatments in orthopaedic medicine and the orthopaedic device industry, enabling the development of personalised implants and accelerating the supply chain of device companies.
TRANSITION aims to develop a hybrid device consisting of a titanium core (providing mechanical integrity) overlaid by a layer of functional tissue (engineered bone and articular cartilage), which will be particularly suited to hip and knee implants.
In working towards this aim the project team will strive to advance the underpinning science and technology of metal, polymer and biological 3D-printing as well as surface treatments and functional coatings.
Improving existing implant technologies
These advances will have direct benefits for improving existing implant technologies in parallel to the end goal. A key goal is to have a subset of products ready for regulatory submission and clinical studies by the end of the research programme.
Professor Michael Morris, AMBER director said: “TRANSITION will build on the combined expertise of both AMBER Investigators and the Johnson & Johnson Family of Companies in manufacturing, surface science, biomaterials, tissue engineering and 3D bioprinting to develop new classes of medical devices.
“The Spokes programme will leverage key infrastructure in the two new laboratories established by AMBER in Ireland: the new 3D bioprinting lab being established and funded by the Johnson & Johnson Family of Companies and Trinity, and our new AR-Lab (Additive Research) laboratory.”
Professor Danny Kelly, AMBER’s lead principal investigator on the project, who is also a professor in the School of Engineering, said: “Realising the ambitious goal of a new hybrid device to replace diseased joints will require addressing existing challenges in the 3D printing of metals, biodegradable polymers, bio-inks and cells, and subsequently integrating the printing processes of these diverse material sets to develop hybrid metal-biological devices capable of restoring joint function.
Transform the production of metallic orthopaedic devices
“In doing so, this programme of research will transform the production of metallic orthopaedic devices used in hip and knee arthroplasty and has the potential to transform how we treat degenerative diseases such as osteoarthritis.”
Osteoarthritis (OA), the most common form of arthritis, is a serious disease of the joints affecting nearly 10 per cent of the population worldwide. At present the treatment option for end-stage OA is limited to surgical replacement of the diseased joint with a metal and polymer prosthesis.
Although the outcomes of such operations are generally excellent, revision surgery is not uncommon, especially for younger, more active patients where due to age and lifestyle their initial implant is likely to require replacement. Given that the number of total hip arthroplasties performed annually is predicted to double over the next 25 years, innovative new approaches are necessary.
Builds on the work of Innovation Centre in Cork
Euan Thomson, head of R&D, Johnson & Johnson Medical Devices Companies, said: “This strategic collaboration builds on the work of our Innovation Centre in Cork and will help identify healthcare solutions that will ultimately enable us to advance care for patients through transformative technologies.
“Our collaboration with these industry-leading experts will allow our teams in Ireland and across the globe to further our extensive research into 3D printing for therapeutic use, not only in the orthopaedics space, but across our entire Johnson & Johnson portfolio.”
SFI’s Spokes programme enables the addition of new industrial and academic partners and projects to an SFI Research Centre. TRANSITION will enable the employment of seven postdoctoral researchers and 10 PhD students. It involves academics from Trinity (Professor Danny Kelly [lead], Professor Mick Morris, Professor David Hoey, Professor Conor Buckley, Professor Garret O’Donnell, Dr Rocco Lupoi, Dr David Trimble), RCSI (Professor Fergal O’Brien), DCU (Professor Myles Turner) and UCD (Dr Eoin O’Cearbhaill, and Professor Pieter Bramaa).http://www.engineersjournal.ie/2018/09/04/amber-announces-research-collaboration-transform-orthopaedic-treatments/http://www.engineersjournal.ie/wp-content/uploads/2018/08/a-am.jpghttp://www.engineersjournal.ie/wp-content/uploads/2018/08/a-am-300x300.jpgNews3D Printing,AMBER,SFI,TCD